BR102020024378A2 - Synthetic peptide antigen p.sc2.s.309 applied in kit and elisa method for serological diagnosis of covid-19 - Google Patents

Synthetic peptide antigen p.sc2.s.309 applied in kit and elisa method for serological diagnosis of covid-19

Info

Publication number
BR102020024378A2
BR102020024378A2 BR102020024378A BR102020024378A BR102020024378A2 BR 102020024378 A2 BR102020024378 A2 BR 102020024378A2 BR 102020024378 A BR102020024378 A BR 102020024378A BR 102020024378 A BR102020024378 A BR 102020024378A BR 102020024378 A2 BR102020024378 A2 BR 102020024378A2
Authority
BR
Brazil
Prior art keywords
covid
kit
synthetic peptide
test
diagnostic
Prior art date
Application number
BR102020024378A
Other languages
Portuguese (pt)
Other versions
BR102020024378B1 (en
Inventor
Castello Branco Beirão Breno
Ricardo Soccol Carlos
Lucas Pires Ramos Eliezer
Do Nascimento Ferreira Gabriela
Michel Dela Vedova Costa Jean
Porto De Souza Vandenberghe Luciana
Hospinal Santiani Manuel
Max Ingberman
Aparecido Boschero Raphael
Thomaz Soccol Vanete
Original Assignee
Imunova Analises Biologicas Ltda
Univ Federal Parana
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imunova Analises Biologicas Ltda, Univ Federal Parana filed Critical Imunova Analises Biologicas Ltda
Priority to BR102020024378-0A priority Critical patent/BR102020024378B1/en
Priority claimed from BR102020024378-0A external-priority patent/BR102020024378B1/en
Publication of BR102020024378A2 publication Critical patent/BR102020024378A2/en
Publication of BR102020024378B1 publication Critical patent/BR102020024378B1/en

Links

Abstract

antígeno peptídeo sintético p.sc2.s.309 aplicado em kit e método elisa para diagnóstico sorológico de covid-19. frente ao panorama da pandemia de covid-19 há a necessidade de alternativas de diagnóstico. a presente invenção descreve um kit e método diagnóstico sorológico para covid-19. esta utiliza como antígeno o peptídeo sintético p.sc2.s.309 em imunoensaios no formato de teste elisa para identificar imunoglobulina igm em amostras biológicas de humanos, podendo também ser aplicada como teste de avidez. o peptídeo p.sc2.s.309 apresenta sequência artificial altamente similar ao do sars-cov-2 e de baixa similaridade com outros organismos próximos. este kit e seu método de uso apresentam alta sensibilidade (85%) e especificidade (100%) para detecção de igm. além de ser um teste de baixo custo e fácil execução, possibilitando um teste diagnóstico eficiente mais acessível.synthetic peptide antigen p.sc2.s.309 applied in kit and elisa method for serological diagnosis of covid-19. given the panorama of the covid-19 pandemic, there is a need for diagnostic alternatives. The present invention describes a serological diagnostic kit and method for covid-19. this uses the synthetic peptide p.sc2.s.309 as antigen in immunoassays in the elisa test format to identify igm immunoglobulin in biological samples from humans, and can also be applied as an avidity test. the peptide p.sc2.s.309 has an artificial sequence highly similar to that of sars-cov-2 and of low similarity to other nearby organisms. this kit and its method of use have high sensitivity (85%) and specificity (100%) for the detection of igm. in addition to being a low cost test and easy to perform, allowing an efficient diagnostic test more accessible.

BR102020024378-0A 2020-11-30 SYNTHETIC PEPTIDE ANTIGEN P.SC2.S.309 APPLIED IN KIT AND ELISA METHOD FOR SEROLOGICAL DIAGNOSIS OF COVID-19 BR102020024378B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR102020024378-0A BR102020024378B1 (en) 2020-11-30 SYNTHETIC PEPTIDE ANTIGEN P.SC2.S.309 APPLIED IN KIT AND ELISA METHOD FOR SEROLOGICAL DIAGNOSIS OF COVID-19

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR102020024378-0A BR102020024378B1 (en) 2020-11-30 SYNTHETIC PEPTIDE ANTIGEN P.SC2.S.309 APPLIED IN KIT AND ELISA METHOD FOR SEROLOGICAL DIAGNOSIS OF COVID-19

Publications (2)

Publication Number Publication Date
BR102020024378A2 true BR102020024378A2 (en) 2022-05-10
BR102020024378B1 BR102020024378B1 (en) 2023-08-22

Family

ID=

Similar Documents

Publication Publication Date Title
Elshemey et al. Evaluation of a rapid immunochromatographic test for detection of Brucella abortus antibodies in Egyptian cattle sera and milk.
Samartino et al. Validation of enzyme-linked immunosorbent assays for the diagnosis of bovine brucellosis
Rhodes et al. Comparative study of IFNγ and antibody tests for feline tuberculosis
DE60331677D1 (en) KIT FOR THE STUDY OF HUMAN LOW MOLECULAR WEIGHT CD14 AND ANTIBODIES
Hezarjaribi et al. Serological evidence of human cystic echinococcosis and associated risk factors among general population in Mazandaran Province, northern Iran
ES512498A0 (en) "METHOD AND ITS CORRESPONDING DEVICE FOR THE TESTING OF ANTIBODIES WITH RESPECT TO SOLUBLE ANTIGENS".
Day Introduction to antigen and antibody assays
Julián et al. An ELISA for five glycolipids from the cell wall of Mycobacterium tuberculosis:: Tween 20 interference in the assay
Kabeer et al. Interferon gamma and interferon gamma inducible protein-10 in detecting tuberculosis infection
Kumar et al. Development of the Com1 synthetic peptide-based Latex Agglutination Test (LAT) and its comparative evaluation with commercial indirect-ELISA for sero-screening of coxiellosis in cattle
Cooper et al. ELISA and immuno–polymerase chain reaction assays for the sensitive detection of melioidosis
García-Bocanegra et al. Evaluation of different enzyme-linked immunosorbent assays for the diagnosis of brucellosis due to Brucella melitensis in sheep
BR102020024378A2 (en) Synthetic peptide antigen p.sc2.s.309 applied in kit and elisa method for serological diagnosis of covid-19
BR9507389A (en) Method for detecting the presence of a mycobacterium species and a kit and antibodies for use in it
BR102020024403A2 (en) Synthetic peptide antigens for the diagnosis of sars-cov-2
ATE304607T1 (en) DETECTION OF PYRUVATE KINASE ISOENZYME IN CHEESE
ATE282830T1 (en) IMMUNE TEST FOR HUMAN CHROMOGRANINE A (CGA), ANTIBODIES, REAGENT AND SUITABLE TEST SET
Turner et al. Serological speciation of human schistosome infections by ELISA with a panel of three antigens
Minas et al. Validation of a competitive ELISA for diagnosis of Brucella melitensis infection in sheep and goats
Rodrigo et al. A new application of Streptavidin ImmunoCAP® for measuring IgG antibodies against non-available commercial antigens
Redhuan et al. Salivary anti-50 kDa antibodies as a useful biomarker for diagnosis of typhoid fever
Rokni et al. Comparative evaluation of Fast enzyme linked immunosorbent assay (Fast-ELISA) and standard-ELISA for the diagnosis of human hydatidosis
Andrae et al. Antigen detection in canine blastomycosis: comparison of different antibody-antigen combinations in two competitive ELISAs
Shaheen et al. Evaluation of the response of human humoral antibodies to Salmonella typhi lipopolysaccharide in an area of endemic typhoid fever
van Knapen et al. Detection of toxoplasma antigen in tissues by means of enzyme-linked immunosorbent assay (ELISA)

Legal Events

Date Code Title Description
B03B Publication of an application: publication anticipated [chapter 3.2 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/11/2020, OBSERVADAS AS CONDICOES LEGAIS

B22L Other matters related to patents and certificates of addition of invention: notification of licence offer (art 64 par 1 of lpi)

Free format text: CONDICOES CONTRATUAIS: 1) ROYALTIES: 5% (CINCO POR CENTO) DO PRECO DE VENDA, LIVRE DE IMPOSTOS; 2) PRAZO: ATE O TERMINO DE VIGENCIA DA PATENTE, EM 30/11/2040; 3) CONDICOES DE PAGAMENTO: ANUAL EM FUNCAO DAS VENDAS APURADAS NO PERIODO; 4) DISPONIBILIDADE DE "KNOW-HOW": SIM; 5) ASSISTENCIA TECNICA: NAO. --- OBS: CONSULTA A CARTA PATENTE PODERA SER FEITA ATRAVES DO ENDERECO ELETRONICO WWW.INPI.GOV.BR - NO ACESSO RAPIDO = BUSCA DE PROCESSOS = FACA LOGIN COM SENHA OU TECLE CONTINUAR = PATENTE = DIGITE O NUMERO DO PROCESSO = PESQUISAR. PARA ACESSAR, CADASTRE-SE NO PORTAL DO INPI.

B22L Other matters related to patents and certificates of addition of invention: notification of licence offer (art 64 par 1 of lpi)

Free format text: CONDICOES CONTRATUAIS: 1) ROYALTIES: 5% (CINCO POR CENTO) DO PRECO DE VENDA, LIVRE DE IMPOSTOS; 2) PRAZO: ATE O TERMINO DE VIGENCIA DA PATENTE, EM 30/11/2040; 3) CONDICOES DE PAGAMENTO: ANUAL EM FUNCAO DAS VENDAS APURADAS NO PERIODO; 4) DISPONIBILIDADE DE KNOW-HOW: SIM; 5) ASSISTENCIA TECNICA: NAO. --- OBS: CONSULTA A CARTA PATENTE PODERA SER FEITA ATRAVES DO ENDERECO ELETRONICO WWW.INPI.GOV.BR - NO ACESSO RAPIDO = BUSCA DE PROCESSOS = FACA LOGIN COM SENHA OU TECLE CONTINUAR = PATENTE = DIGITE O NUMERO DO PROCESSO = PESQUISAR. PARA ACESSAR, CADASTRE-SE NO PORTAL DO INPI.